spacer
home > pmps > spring 2018 > protective packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Protective Packaging

Pharmaceutical companies and their logistics partners are enjoying more availability and scope of temperature-controlled distribution lanes within pharma supply chains than ever before. This means more choice when specifying thermal protection solutions that are both cost-effective and fit for purpose.

This has led to the current trend of moving away from temperature-controlled packaging, particularly as well-controlled distribution lanes and effective thermal covers become the norm. Designed to provide a greater level of protection within uncontrolled distribution lanes and general cargo facilities, temperature-controlled packaging can be costly and offer low payload efficiency, particularly for controlled distribution lanes where they are often over-engineered and provide a higher level of protection than actually required.

As a result, thermal protection solutions are becoming increasingly popular. However, this is bringing its own set of challenges, including a lack of a consistent approach to product performance assessment.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kevin Valentine is Chief Technology Officer at TP3 Global and Cool Logistics India. He has been working in the temperature-controlled packaging industry for over 26 years. Following a 10 year career at Laminar Medica, Kevin founded Cool Logistics in 2000. He joined Cool Logistics India and TP3 Global in 2016, where he has led the development of a new technical centre to provide enhanced technical services to customers. Kevin has also overseen the creation of several new products for improved thermal protection of pharmaceutical products and other temperature-sensitive cargo.
spacer
Kevin Valentine
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine

VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developerís mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Medical Device USA 2018

11-12 July 2018, Minneapolis, Minnesota

6th Outsourcing in Clinical Trials conference is the only clinical outsourcing platform for medical device companies within Medical Alley this year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement